banner
FGFR inhibitor BGJ398, Purity ≥98%
Inquiry

Cat. No.: X24-06-ZQ072

FGFR inhibitor BGJ398, Purity ≥98%

Synonym: 872511-34-7; FGFR inhibitor; BGJ-398

  • MDL: MFCD22123241
  • CAS Number: 872511-34-7
  • Compound CID: 53235510
img
Product Size
5 mg; 10 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
BGJ398, soluble in warmed DMSO and insoluble in water and ethanol, is a protein tyrosine kinase inhibitor that has shown potent biochemical activity against FGFR. It targets FGFR2, FGFR3, Abl, FGFR1, FGFR3 (K650E), FGFR4, Fyn, Kit, LCK, Lyn, and VEGFR2.
Molecular Weight
560.48
Molecular Formula
C26H31Cl2N7O3
Targets
FGFR2: 1.4 nM; FGFR3: 1.0 nM; Abl: 2.3 nM; FGFR1: 0.9 nM; FGFR3 (K650E): 4.9 nM; FGFR4: 60 nM; Fyn: 1.9 μM; Kit: 0.75 μM; LCK: 2.5 μM; Lyn: 0.30 μM; VEGFR2: 0.18 μM
Form
Lyophilized powder
Purity
≥98%
Solubility
Warmed DMSO: 1 mg/mL (1.78 mM); Water: Insoluble; Ethanol: Insoluble
Identity
Confirmed by NMR/HPLC/MS.
Applications
BGJ398 is employed as an FGFR inhibitor, offering avenues for research into targeted cancer therapies.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0